PRNewsWire
10 Feb 2026, 14:00 UTC · 32w ago
Verdict
Headline leans bullish. We score BLLN +1.00 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+1.00strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish
BillionToOne (BLLN) launched two new add-on liquid biopsy applications, Northstar PGx and Northstar Select CH, to expand the capabilities of its Northstar Select platform.
More positive than 77% of claims this week
The Northstar Select CH application achieves over 99% accuracy in distinguishing tumor-derived alterations from non-tumor findings (clonal hematopoiesis).
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
More positive than 63% of claims this week
Northstar PGx integrates pharmacogenomic testing for DPYD and UGT1A1 genes into the existing liquid biopsy workflow with a 5-day average turnaround time.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company announced the expansion of its Northstar platform with two new liquid biopsy applications, enhancing its clinical utility and competitive positioning.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
3h ago
+23.8%
Price agrees with the score
$114.42 vs $92.41 close before publication (Feb 9) · not market-adjusted
BLLN chart →
